disease areas
Leading the way to early diagnosis.
Leading the way to early diagnosis.
The damage to joints caused by RA is irreversible. We are focused on identifying biomarkers to diagnose RA at the onset of the disease to avoid joint erosions and other damage. QUANTA Flash® and QUANTA Lite® CCP3 assays aid in the early diagnosis of this disease, where prompt initiation of treatment can greatly benefit patients.
HIGHLIGHTS
- Giving patients earlier answers.We help improve patient care by providing tests that can aid in the early diagnosis of RA for prompt treatment.
- Accurate lab results.Labs feel good knowing that our RA assays aid in early disease detection while delivering highly accurate results.
- Bringing clinicians more options.Clinicians appreciate our research into new biomarkers that may provide additional insight into diagnosis, prognosis and disease activity monitoring for RA.
Related Systems
BIO-FLASH®
BIO-FLASH®
Autoimmune chemiluminescent (CIA) analyzer eliminates batching and provides precise quantification.
QUANTA-Lyser® 160/240 EIA/IFA Processors
QUANTA-Lyser® 160/240 EIA/IFA Processors
Flexible EIA/IFA processing platform to meet the volume requirements of your laboratory
QUANTA-Lyser® 2
QUANTA-Lyser® 2
QUANTA-Lyser® 2 is the ideal platform for esoteric assays or in settings that require maximum flexibility and efficiency
QUANTA-Lyser® 3000
QUANTA-Lyser® 3000
QUANTA-Lyser 3000 is a high throughput EIA/IFA that give you the ability to complete your workload faster with less hands-on time.
**For Sale in the USA ONLY